SEQUENCE LISTING

<110> RA PHARMACEUTICALS, INC.

<120> NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS

<130> 2011.1035PCT

<140> PCT/US2019/XXXXXX
<141> 2019-10-22

<150> 62/899,864
<151> 2019-09-13

<150> 62/844,388
<151> 2019-05-07

<150> 62/837,974
<151> 2019-04-24

<150> 62/815,575
<151> 2019-03-08

<150> 62/777,524
<151> 2018-12-10

<150> 62/748,659
<151> 2018-10-22

<160> 1

<170> PatentIn version 3.5

<210> 1
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"

<220>
<223> N-term Ac

<220>
<221> SITE
<222> (1)..(6)
<223> /note="Lactam bridge between residues"

<220>
<221> MOD_RES
<222> (7)..(7)

<223> N-methyl-aspartic acid

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Tert-butylglycine

<220>
<221> MOD_RES
<222> (10)..(10)
<223> 7-azatryptophan

<220>
<221> MOD_RES
<222> (14)..(14)
<223> Cyclohexylglycine

<220>
<221> MOD_RES
<222> (15)..(15)
<223> N-epsilon-(PEG24-gamma-glutamic acid-N-alpha-hexadecanoyl)Lys

<400> 1
Lys Val Glu Arg Phe Asp Xaa Xaa Tyr Xaa Glu Tyr Pro Xaa Lys
1 5 10 15